In today's AI-dominated context and where launch is more complex than ever, the margin for error is shrinking. However, there’s a growing appreciation that a launch leader’s ability to optimize and impact launch trajectory is on the rise.

That gap between seeing a signal and making a decision was the central tension explored in the first episode of the Summit Series, hosted by Paul Simms of Impatient Health, featuring launch leaders from Pfizer, AstraZeneca, and Grifols alongside Within3 CEO Lance Hill.

The conversation moved from live poll data to a candid debate. It's a practical look at what launch leadership actually requires when the plan meets reality.